Biogen's ad on NYT Magazine directing readers to a 'symptoms quiz' (Zachary Brennan for Endpoints News)
Biogen wasted no time in rolling out a ‘disease awareness’ campaign for Alzheimer's as an R&D marathon turns into a sprint. A top analyst awards gold, silver and bronze
Biogen and the FDA found a way to stir a tempest of controversy and dismay over the accelerated approval of an unproven Alzheimer’s drug …
This article is available only to Premium subscribers
Upgrade to Premium for unlimited access and Premium exclusives.
